Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP: Staged Treatment in Early Psychosis
NCT02751632Phase 3Completed
- Sponsor
- Orygen
- Start
- Apr 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluoxetine in psychosis (7 arms), sponsored by Orygen. Primary endpoint: Global Functioning Scale Score at 6 months. Started Apr 2016; status: completed.
02
Drugs
fluoxetine
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT02751632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751632.